There were 553 press releases posted in the last 24 hours and 170,571 in the last 365 days.

Varicella Live Vaccine Market Size is Expected to Reach $4.22 Billion by 2026

Rise in immunization programs worldwide, increase in awareness regarding use of varicella live vaccines, and surge in adoption of varicella live vaccines fuel the growth of the global varicella live vaccine market. Based on product, the monovalent varicella vaccine segment would remain lucrative throughout the forecast period. Based on geography, the Asia-Pacific region would grow at the fastest CAGR of 7.0% by 2026.

/EIN News/ -- Portland, OR, Nov. 07, 2019 (GLOBE NEWSWIRE) -- According to the report, the varicella live vaccine market was estimated at $2.71 billion in 2018 and is expected to hit $4.22 billion by 2026, registering a CAGR of 5.7% during the study period. The report offers a detailed analysis of the top winning strategies, top investment pockets, drivers & opportunities, market size & estimations, competitive landscape, and wavering market trends.

Increase in immunization programs across the globe, the surge in awareness regarding the use of varicella live vaccines, and rise in adoption of varicella live vaccines are the major factors driving the growth of the global varicella live vaccine market. On the other hand, high monetary inputs associated with the production restrains the growth to some extent. However, high growth potential in emerging economies has paved the way for a number of opportunities in the industry.

Request Report Sample at

The monovalent varicella vaccine segment to remain lucrative by 2026-

Based on the product, the monovalent varicella vaccine segment accounted for nearly two-thirds of the total market revenue in 2018 and is expected to retain its dominance till 2026. The same segment would also grow at the fastest CAGR of 5.9% during the estimated period.

The chickenpox immunization segment to lead the trail-

Based on the application, the chickenpox immunization segment contributed to nearly three-fifths of the total market share in 2018 and is anticipated to dominate throughout 2019–2026. The herpes zoster segment, on the other hand, would showcase the fastest CAGR of 9.8% during the study period.

North America to rule the roost in terms of revenue-

Based on geography, North America held the major share in 2018, accounting for more than two-fifths of the total market. Simultaneously, the region across Asia-Pacific would cite the fastest CAGR of 7.0% during 2019–2026.

Do Purchase Enquiry at

Frontrunners in the industry-

Key market players analyzed in the global varicella live vaccine market report include

  • GlaxoSmithKline plc,
  • Changchun BCHT Biotechnology Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Green Cross Holdings (GC Pharma)
  • Emcure Pharmaceuticals Limited
  • Merck & Co. Inc.
  • Bio-Med Pvt. Limited
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
  • Novo Medi Sciences Pvt. Ltd.
  • Sanofi

These players have taken recourse to high-end market strategies such as partnerships, collaboration, mergers & acquisitions, and new product launch to brace their stand in the industry.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Follow Us on LinkedIn:
Follow Us on Twitter: 

Primary Logo

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.